Two promising medications in this field are cagrilintide and tirzepatide
GLP-1 agonists, such as Ozempic, Trulicity, and Rybelsus, are a class of medications that mimic the GLP-1 compound we naturally create in our bodies
On the other hand, the emerging proteolysis targeting chimera (PROTAC) technology, which was introduced by Crews and Deshaies in 2001 via disrupting the endogenous ubiquitin (Ub)-E2 ligase-E3 ligase complex [174], which is widely applicable for degrading abnormal protein targets including epigenetic proteins, may show promise in the treatment of epilepsy
The formula addresses the specific deficiencies that research has identified in GLP-1 users: vitamin D, iron, B vitamins, zinc, and magnesium
Its important, however, to put this analysis into the proper context